Takaishi Koji, Muto Tomoya, Mimura Naoya, Takiguchi Jun, Nagao Yuhei, Oshima-Hasegawa Nagisa, Tsukamoto Shokichi, Takeda Yusuke, Mitsukawa Shio, Takeuchi Masahiro, Ohwada Chikako, Ota Satoshi, Iseki Tohru, Nakaseko Chiaki, Sakaida Emiko
Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan.
Int J Hematol. 2018 Oct;108(4):452-455. doi: 10.1007/s12185-018-2471-x. Epub 2018 May 21.
Mediastinal gray zone lymphoma (MGZL) is a provisional entity with intermediate features between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma. Outcomes for patients with MGZL are reportedly poorer than those for patients with cHL or primary mediastinal large B-cell lymphoma. Additionally, no standard management guidelines for patients with MGZL are available, primarily due to its recent identification, rarity, and challenges in diagnosis. Although recent several studies have suggested dose-adjusted EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone, and rituximab) may improve outcomes in patients with MGZL, numerous patients still suffer from relapsed/refractory MGZL, and the optimal management for such patients remains uncertain. Here, we report the first case of successful treatment of refractory MGZL by tandem high-dose chemotherapy supported by autologous stem cell transplantations (auto-SCTs) and consolidative radiotherapy (RT). To date, the patient remains in CR 33 months after the completion of RT, with no significant complications. This case suggests that tandem auto-SCTs may be a promising therapeutic option for relapsed/refractory MGZL.
纵隔灰色地带淋巴瘤(MGZL)是一种具有介于经典霍奇金淋巴瘤(cHL)和弥漫性大B细胞淋巴瘤之间中间特征的暂定实体。据报道,MGZL患者的预后比cHL或原发性纵隔大B细胞淋巴瘤患者的预后更差。此外,目前尚无针对MGZL患者的标准管理指南,主要原因是其最近才被发现、罕见且诊断存在挑战。尽管最近的几项研究表明,剂量调整后的EPOCH-R(依托泊苷、阿霉素、长春新碱、环磷酰胺、泼尼松龙和利妥昔单抗)可能改善MGZL患者的预后,但仍有许多患者患有复发/难治性MGZL,对此类患者的最佳管理仍不确定。在此,我们报告首例通过自体干细胞移植(auto-SCT)和巩固性放疗(RT)支持的串联高剂量化疗成功治疗难治性MGZL的病例。迄今为止,患者在放疗完成33个月后仍处于完全缓解状态,无明显并发症。该病例表明,串联auto-SCT可能是复发/难治性MGZL的一种有前景的治疗选择。